Propensity score-matched comparison of non-anatomical resection and radiofrequency ablation for hepatocellular carcinoma in patients with up to three tumours, each measuring up to 3 cm in diameter

Y. Kato1, Y. Okamura1, K. Omae2, T. Sugiura1, T. Ito1, Y. Yamamoto1, R. Ashida1, R. Sato3, T. Aramaki2 and K. Uesaka1

1Division of Hepato-Biliary-Pancreatic Surgery, 2Clinical Trial Coordination Office and 3Division of Intervention Radiology, Shizuoka Cancer Centre Hospital, Shizuoka, Japan

Correspondence to: Dr Y. Okamura, Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Centre Hospital, 1007, Shimo-Nagakubo, Sunto-Nagaizumi, Shizuoka, 411-8777 Japan (e-mail: yu.okamura@scchr.jp)

Background: Non-anatomical liver resection (NAR) and radiofrequency ablation (RFA) are treatment options for early-stage hepatocellular carcinoma (HCC). The aim was to compare the outcomes of NAR and RFA for HCC in patients with three or fewer tumour nodules, each measuring not more than 3 cm in maximum diameter.

Methods: Eligible patients undergoing NAR or RFA with curative intent between September 2002 and December 2014 were identified. A propensity score-matching analysis was performed to reduce bias, and outcomes in these patients were analysed.

Results: From a total of 199 patients, 1:1 propensity score matching identified 70 matched pairs. Patients having NAR had a longer hospital stay (median 10 days versus 4 days for those who had RFA; \( P < 0.001 \)) and a higher morbidity rate (24% versus 10% respectively; \( P = 0.042 \)). Patients who had NAR had slightly better recurrence-free survival but this failed to reach statistical significance in univariable analysis (\( P = 0.064 \)). There was no significant difference in overall survival between the two groups (\( P = 0.475 \)). RFA was identified as an independent risk factor for recurrence-free survival (hazard ratio (HR) 1.57; \( P = 0.041 \)) in multivariable analysis. Local recurrence was significantly more common in patients receiving RFA (23% versus 1% per cent; \( P < 0.001 \)).

Conclusion: RFA was an independent risk factor for shorter recurrence-free survival, with a significantly higher local recurrence rate than NAR. Despite these differences, overall survival was not affected.

Funding information
No funding

Paper accepted 22 February 2018
Published online 28 May 2018 in Wiley Online Library (www.bjsopen.com). DOI: 10.1002/bjs5.60

Introduction

Hepatectomy can be performed with low operative mortality and morbidity rates,\(^1,2\) Surgical resection is therefore considered the standard treatment for hepatocellular carcinoma (HCC) in patients with adequate hepatic functional reserve, and offers patients the chance of long-term survival.\(^3,4\) Radiofrequency ablation (RFA) has become a popular treatment option for patients with early-stage HCC owing to its low complication rate and cost-effectiveness,\(^5,6\) particularly in patients with multiple small tumours.\(^7,8\) The American Association for the Study of Liver Diseases guidelines\(^9\) and European Association for the Study of the Liver (EASL)\(^10\) recommend RFA together with surgical resection for early-stage HCC.

Whether surgical resection or RFA should be selected as the first therapeutic choice for patients with early-stage HCC remains controversial. To date, three RCTs\(^11–13\) and several retrospective studies\(^14–16\) comparing RFA with surgical resection have been reported, with contradictory findings reflecting different inclusion criteria.

Regarding method of hepatectomy, the EASL recommends anatomical resection and, although some studies\(^17–20\) have reported survival benefits with...
anatomical resection, others\textsuperscript{21–24} have been unable to do so. Non-anatomical resection (NAR) is an attractive treatment option for patients with cirrhotic livers, so a comparison of NAR and RFA seems appropriate in the context of achieving local control. Only one study\textsuperscript{25}, which included only 17 patients in each group after matching, has compared RFA with NAR.

The purpose of this study was to compare the long-term outcomes of patients treated with NAR and RFA as initial therapy for HCC in patients with three or fewer tumours, each with a maximum diameter of not more than 3 cm, using propensity score matching.

**Methods**

Patients with HCC who had three or fewer tumours, each measuring not more than 3 cm, were identified from the surgical database of hepatectomies undertaken at the Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Centre Hospital, between September 2002 and December 2014. Patients who underwent anatomical resection were excluded and the remaining patients formed the NAR group. Patients who had undergone RFA as initial treatment at the Division of Interventional Radiology, Shizuoka Cancer Centre Hospital, in the same interval were identified, and those with the same tumour characteristics as the NAR group selected for comparison to achieve 1:1 matching. The institutional review board approved this study and waived the need for informed consent.

Pretreatment blood samples were drawn on admission (in principle within 2 days before treatment). Serum albumin values were measured, as well as total bilirubin, aspartate aminotransferase (AST), alanine aminotransferase, \(\alpha\)-fetoprotein (AFP), des-\(\gamma\)-carboxy prothrombin (DCP), hepatitis C virus antibody, hepatitis B virus surface antigen, platelet count and prothrombin time. Other patient-related variables included age, sex and Child–Pugh classification\textsuperscript{26}.

The diagnosis of HCC was predominantly based on imaging. Patients underwent ultrasonography, dynamic CT and dynamic MRI. Liver nodules showing hyper-attenuation in the arterial phase of the dynamic study and washout in the portal or delayed phase were considered HCC. When a dynamic enhanced pattern was inconclusive, contrast-enhanced ultrasonography was added.

**Treatment**

Indications for treatment were based on the size, number and location of tumours, and hepatic reserve assessment, discussed at a weekly conference involving surgeons, oncologists and radiologists. The extent of hepatectomy was largely determined using Makuuchi’s criteria\textsuperscript{27}, and was usually undertaken by ultrasonic dissection in combination with a Pringle manoeuvre, with clamping for 15 min followed by 5 min declamping.

Patients in the RFA group were treated percutaneously using a 17-G Cool-tip\textsuperscript{TM} RFA system (Covidien, Tokyo, Japan) or LeVeen\textsuperscript{TM} RF system 3000\textsuperscript{TM} (Boston Scientific,
Table 1 Patient demographics and preoperative laboratory analyses after propensity score matching

|               | NAR (n = 70) | RFA (n = 70) | P†  |
|---------------|--------------|--------------|-----|
| Age (years)*  | 68 (39–79)   | 70 (27–85)   | 0.482|
| Sex ratio (M:F)| 55:15        | 53:17        | 0.841;|
| Multiple tumours | 11 (16)     | 10 (14)      | 1.000;|
| Tumour size (mm)* | 20 (9–30)   | 20 (6–30)    | 0.604|
| Hepatic virus infection | 56 (80)    | 61 (87)      | 0.362;|
| Child–Pugh grade B | 1 (1)      | 1 (1)        | 1.000;|
| α-Fetoprotein (ng/ml)* | 4.2 (2.9–4.9) | 4.1 (3.1–5.0) | 0.792|
| Des-γ-carboxy prothrombin (arbitrary units/ml)* | 44 (11–281) | 40 (7–196) | 0.331|
| Albumin (g/dl)* | 4.1 (3.1–5.0) | 4.1 (3.1–5.0) | 0.792|
| Aspartate aminotransferase (units/l)* | 40 (7–196) | 0.331 |
| Alanine aminotransferase (units/l)* | 44 (11–281) | 40 (7–196) | 0.331|
| Total bilirubin (mg/dl)* | 0.7 (0.3–2.3) | 0.7 (0.2–1.5) | 0.618|
| Platelet count (× 10⁴/μl)* | 88 (59–117) | 85 (60–108) | 0.748|
| Prothrombin time (%)* | 88 (59–117) | 85 (60–108) | 0.748|

Values in parentheses are percentages unless indicated otherwise; *values are median (range). NAR, non-anatomical resection; RFA, radiofrequency ablation. †Mann–Whitney U test, except ‡χ² test and §Fisher’s exact test.

Marlborough, Massachusetts, USA). Generator settings were set in accordance with the manufacturer’s instructions, which were based on impedance. For example, if a 3-cm needle was used with the Cool-tip™ system, ablation was started at 40 W and increased by 10 W/min until ablation was complete. Ultrasound-guided puncture was usually performed, although CT-guided puncture was used when the tumours could be detected only by CT.

Table 2 Complications, recurrences and further treatments

|               | NAR (n = 70) | RFA (n = 70) | P‡  |
|---------------|--------------|--------------|-----|
| Duration of hospital stay after treatment (days)* | 10 (3–55) | 4 (1–9) | < 0.001;|
| Morbidities | 17 (24) | 7 (10) | 0.042|
| Additional RFA | 0 | 4 |
| Pneumothorax | 0 | 1 |
| Fever | 3 | 1 |
| Liver dysfunction | 0 | 1 |
| Bile leakage | 4 | 0 |
| Ascites | 5 | 0 |
| Pleural effusion | 1 | 0 |
| Wound infection | 2 | 0 |
| Other complications | 2 | 0 |
| Patients with any recurrence† | 42 (60) | 47 (67) | 0.482|
| Remnant liver (except local area) | 41 (59) | 29 (41) | 0.063|
| Local recurrence in liver | 1 (1) | 16 (21) | < 0.001;|
| Lung | 1 (1) | 1 (1) |
| Bone | 1 (1) | 1 (1) |
| Peritoneum | 0 (0) | 1 (1) |
| Treatment for local recurrence | 1 | 16 |
| Surgical resection | 0 | 3 |
| RFA | 0 | 8 |
| TACE | 1 | 5 |

Values in parentheses are percentages unless indicated otherwise; *values are median (range). †Some patients had more than one type of recurrence. NAR, non-anatomical resection; RFA, radiofrequency ablation; TACE, trans catheter arterial chemoembolization. ‡χ² test, except §Mann–Whitney U test and ¶Fisher’s exact test.

Fig. 2 Survival analysis according to treatment group: a recurrence-free and b overall survival in patients who had non-anatomical liver resection (NAR) or radiofrequency ablation (RFA). a P = 0.064, b P = 0.475 (log rank test)
Table 3  Univariable and multivariable analyses for recurrence-free and overall survival

|                                | Recurrence-free survival | Overall survival |
|--------------------------------|----------------------------|-----------------|
|                                | n  | Univariable P* | Hazard ratio | P   | n  | Univariable P* | Hazard ratio | P   |
| Age (years)                    |    |               |              |     |    |               |              |     |
| ≥ 70                           | 73 | 0.192         |              |     | 0.003 | 2.24 (1.23, 4.06) | 0.008 |
| < 70                           | 67 |               |              |     | 0.356 |              |              |     |
| Sex                            |    |               |              |     |    |               |              |     |
| M                              | 108| 0.991         |              |     | 0.979 |              |              |     |
| F                              | 32 |               |              |     | 0.979 |              |              |     |
| Tumour number                  |    |               |              |     |    |               |              |     |
| Multiple                       | 21 | 0.347         |              |     | 0.070 | 1.63 (0.84, 3.19) | 0.151 |
| Solitary                       | 119|               |              |     | 0.112 |              |              |     |
| Maximum tumour size (mm)       |    |               |              |     |    |               |              |     |
| ≥ 19                           | 81 | 0.130         |              |     | 0.096 | 1.63 (0.84, 3.19) | 0.532 |
| < 19                           | 59 |               |              |     | 0.112 |              |              |     |
| Hepatic virus infection (B or C)|    |               |              |     |    |               |              |     |
| Yes                            | 117| 0.018         | 1.27 (0.59, 2.77) | 0.536 | 0.096 | 1.11 (0.55, 2.31) | 0.532 |
| No                             | 23 | 0.888         | 1.14 (0.58, 1.96) | 0.630 | 1.00 (reference) |              |     |
| α-Fetoprotein (ng/ml)          |    |               |              |     |    |               |              |     |
| ≥ 17                           | 61 | 0.086         | 1.64 (1.06, 2.53) | 0.026 | 0.102 |              |              |     |
| < 17                           | 79 | 0.009         | 1.00 (reference) |         | 1.00 (reference) |              |     |
| Des-γ-carboxy prothrombin (arbitrary units/ml)* | 58  | 0.006 | 1.55 (1.01, 2.39) | 0.041 | 0.475 |
| < 36                           | 82 |               |              |     | 1.00 (reference) |              |     |
| Albumin (g/dl)                 |    |               |              |     |    |               |              |     |
| < 4.0                          | 50 | 0.001         | 1.83 (1.17, 2.86) | 0.008 | 0.002 | 2.17 (1.23, 3.83) | 0.007 |
| ≥ 4.0                          | 90 |               | 1.00 (reference) |         | 1.00 (reference) |              |     |
| Aspartate aminotransferase (units/l) |    |               |              |     |    |               |              |     |
| ≥ 42                           | 63 | < 0.001       | 2.06 (1.32, 3.21) | 0.001 | 0.026 | 2.08 (0.91, 3.52) | 0.061 |
| < 42                           | 77 | 0.004         | 1.08 (0.52, 2.24) | 0.850 | 0.266 |              |              |     |
| Alanine aminotransferase (units/l) |    |               |              |     |    |               |              |     |
| ≥ 41                           | 72 | 0.004         | 1.08 (0.52, 2.24) | 0.850 | 0.266 |              |              |     |
| < 41                           | 68 |               |              |     | 1.00 (reference) |              |     |
| Total bilirubin (mg/dl)        |    |               |              |     |    |               |              |     |
| ≥ 0.7                          | 74 | 0.320         |              |     | 0.531 |              |              |     |
| < 0.7                          | 66 |               |              |     | 0.531 |              |              |     |
| Platelets (< 10³/μl)           |    |               |              |     |    |               |              |     |
| < 10.7                         | 46 | 0.021         | 1.21 (0.72, 2.04) | 0.468 | 0.165 |              |              |     |
| ≥ 10.7                         | 94 |               | 1.00 (reference) |         | 1.00 (reference) |              |     |
| Prothrombin (%)                |    |               |              |     |    |               |              |     |
| < 80                           | 47 | 0.251         |              |     | 0.568 |              |              |     |
| ≥ 80                           | 93 |               |              |     | 0.568 |              |              |     |
| Treatment                      |    |               |              |     |    |               |              |     |
| RFA                            | 70 | 0.064         | 1.57 (1.02, 2.42) | 0.041 | 0.475 |              |              |     |
| NAR                            | 70 |               | 1.00 (reference) |         | 1.00 (reference) |              |     |

Values in parentheses are 95 per cent confidence intervals. RFA, radiofrequency ablation; NAR, non-anatomical resection. *Log rank test; †Cox proportional hazards model.

Contrast-enhanced CT was carried out the day after RFA to confirm the adequacy of the ablated margin. If residual tumour was detected, RFA was repeated that day.

Patients subsequently underwent physical examinations and blood tests for AFP and DCP every 3 months. Serial CT or liver ultrasonography was performed in each patient every 3–6 months. Local recurrence in the liver was diagnosed when a tumour was identified at or adjacent to the initial treatment site (Fig. 1). Patients with recurrence were re-treated subject to their performance status and wishes. Recurrence-free survival (RFS) was defined as the time between the first curative treatment of HCC and confirmation of recurrence. Overall survival (OS) was defined as the time between the first curative treatment and death from any cause.

**Statistical analysis**

To reduce the influence of potential confounders, propensity scores were generated using binary logistic regression.
Independent variables entered into the propensity model included age, Child–Pugh grade, serum albumin level, serum AST level and prothrombin time.

Continuous variables, presented as median (range), were compared using the Mann–Whitney U test. The $\chi^2$ test or Fisher's exact test, as appropriate, was used for analysis of categorical variables. Cumulative RFS and OS curves were calculated using the Kaplan–Meier method and compared using the log rank test. A Cox proportional hazards model was used for univariable and multivariable analyses; all factors found to be significant predictors of recurrence and survival ($P < 0.100$) in the univariable analysis were entered into the multivariable model. The multivariable analysis was performed according to the logistic regression method using a backward stepwise selection model. All statistical analyses were undertaken in SPSS® version 24.0 (IBM, Armonk, New York, USA), and $P < 0.050$ in two-tailed tests was considered significant.

**Results**

Of 199 patients who underwent NAR (70) or RFA (129) as the initial treatment for HCC, and who satisfied the entry criteria, 70 in the RFA group were matched with 70 patients in the NAR group. The pretreatment factors became balanced between the two groups (Table 1).

The duration of hospital stay after treatment was significantly longer in the NAR group than in the RFA group (median 10 versus 4 days respectively; $P < 0.001$). Postoperative morbidity occurred more frequently in the NAR group (24 versus 10 per cent; $P = 0.042$). The specific morbidities were characteristic of each treatment (Table 2).

Median RFS was 26.1 and 16.1 months in the NAR and RFA groups respectively, although this did not reach statistical significance ($P = 0.064$) (Fig. 2a). Among factors with $P < 0.100$ for RFS in the univariable analysis, multivariable analysis indicated that RFA was independently associated with shorter RFS (hazard ratio (HR) 1.57, 95 per cent c.i. 1.02 to 2.42; $P = 0.041$), along with serum DCP level at least 36 arbitrary units/ml, serum AST level 42 units/l or more, and serum albumin level below 4.0 g/dl (Table 3).

Median OS times were 59.5 and 45.4 months in the NAR and RFA groups respectively, with no significant difference between the groups ($P = 0.475$) (Fig. 2b). Multivariable analysis showed that age at least 70 years (HR 2.24, 1.23 to 4.06; $P = 0.008$) and serum albumin level below 4.0 mg/dl (HR 2.17, 1.23 to 3.83; $P = 0.007$) were independently associated with OS (Table 3), but RFA treatment was unrelated to OS.

Forty-two patients (60 per cent) in the NAR group and 47 (67 per cent) in the RFA group developed recurrence in the liver or at any other site over the entire observation period (Table 2). Local recurrence was significantly less frequent in the NAR group than in the RFA group (1 versus 23 per cent; $P < 0.001$), with local recurrences in one and 16 patients respectively. All patients who had local recurrence underwent additional treatment to the local sites in the liver (Table 2).

**Discussion**

The present study showed that, in matched patient groups, RFA treatment was an independent risk factor for local recurrence in the liver, but without impact on overall survival.

A recent meta-analysis, including three RCTs and several retrospective studies comparing RFA with surgical resection, concluded that RFA was comparable to surgical resection in terms of survival, with lower complication rates but higher recurrence rates, consistent with the present results. A study comparing RFA with surgical resection for solitary small HCC using a propensity score model showed that surgical resection provided better OS and RFS than RFA. Most reports included patients who underwent anatomical resection in the surgical resection group; such patients would generally have better liver function and performance status. The present study deliberately focused on patients thought able to tolerate NAR as an alternative to RFA.

The study showed that NAR resulted in a better RFS than RFA, but was not superior to RFA in terms of OS. The similar OS rates may reflect aggressive further treatments designed to achieve local control, such as repeated RFA and salvage surgical resection. These were used in more than two-thirds of patients with local recurrence in the RFA group.

The Barcelona Clinic Liver Cancer (BCLC) group classifies single HCC smaller than 2 cm into very early-stage disease, and a single lesion or nodules not larger than 3 cm into early-stage HCC. The Japan Society of Hepatology (JSH) recommends surgical resection or RFA for HCC with a maximum diameter of 3 cm and three or fewer tumours, embracing the very early and early-stage in the BCLC classification. The inclusion criteria for the present study matched the definition of the treatment algorithm of the BCLC and JSH.

The present study suggested that NAR should be considered in patients with a lower serum DCP level or a lower serum AST level on the basis of the multivariable analysis for RFS. On the other hand, RFA should be considered in older patients or those with a lower serum albumin...
level, based on the results of multivariable analysis for OS. Shorter hospital stay and lower rates of morbidity after RFA may be important because of their association with survival in the actual clinical setting.

Despite the present study being balanced and comparative by applying propensity score matching, several limitations warrant mention. The total number of patients was relatively small in both groups (79 patients each). The decision to choose NAR or RFA as the initial treatment was dependent on the patient’s and clinician’s preferences. As a non-randomized observational single-centre study, there was still a possibility of selection bias despite the use of propensity score matching. An RCT to determine the survival benefit of RFA compared with surgical resection is currently in progress (registered at the University Hospital Medical Information Network, identifier: UMIN000001795).

The present study showed superiority of NAR compared with RFA with regard to RFS, but not in terms of OS in patients with early-stage HCC. Clinicians should, nevertheless, consider biochemical profiles and differences in likely complication and recurrence rates when advising patients about these treatments.

Disclosure

The authors declare no conflict of interest.

References

1 Duffy JP, Hiatt JR, Busuttil RW. Surgical resection of hepatocellular carcinoma. Cancer 2008; 14: 100–110.
2 Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008; 49(Suppl 1): S20–S37.
3 Chok KS, Ng KK, Poon RT, Lo CM, Fan ST. Impact of postoperative complications on long-term outcome of curative resection for hepatocellular carcinoma. Br J Surg 2009; 96: 81–87.
4 Pawlik TM, Poon RT, Abdalla EK, Zorzzi D, Ikai I, Curley SA et al.; International Cooperative Study Group on Hepatocellular Carcinoma. Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma. Arch Surg 2005; 140: 450–457.
5 Lau WY, Lai EC. The current role of radiofrequency ablation in the management of hepatocellular carcinoma: a systematic review. Ann Surg 2009; 249: 20–25.
6 Curley SA, Marra P, Beatty K, Ellis LM, Vauthey JN, Abdalla EK et al. Early and late complications after radiofrequency ablation of malignant liver tumors in 608 patients. Ann Surg 2004; 239: 450–458.
7 Lencioni R, Cioni D, Crocetti L, Franchini C, Pina CD, Lera J et al. Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology 2005; 234: 961–967.
8 Omata M, Tateishi R, Yoshida H, Shiina S. Treatment of hepatocellular carcinoma by percutaneous tumor ablation methods: ethanol injection therapy and radiofrequency ablation. Gastroenterology 2004; 127(Suppl 1): S159–S166.
9 Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020–1022.
10 European Association for the Study of the Liver; European Organisation For Research And Treatment Of Cancer. EASL–EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908–943.
11 Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ et al. A prospective randomized trial comparing percutaneous local ablation therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006; 243: 321–328.
12 Huang J, Yan L, Cheng Z, Wu H, Du L, Wang J et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg 2010; 252: 903–912.
13 Feng K, Yan J, Li X, Xia F, Ma K, Wang S et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J Hepatol 2012; 57: 794–802.
14 Peng ZW, Lin XJ, Zhang YJ, Liang HH, Guo RP, Shi M et al. Radiofrequency ablation versus hepatic resection for the treatment of hepatocellular carcinomas 2 cm or smaller: a retrospective comparative study. Radiology 2012; 262: 1022–1033.
15 Hasegawa K, Kokudo N, Makuuchi M, Izumi N, Ichida T, Kudo M et al. Comparison of resection and ablation for hepatocellular carcinoma: a cohort study based on a Japanese nationwide survey. J Hepatol 2013; 58: 724–729.
16 Pompili M, Saviano A, de Matthaeis N, Cucchetti A, Ardito F, Federico B et al. Long-term effectiveness of resection and radiofrequency ablation for single hepatocellular carcinoma ≤3 cm. Results of a multicenter Italian survey. J Hepatol 2013; 59: 89–97.
17 Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907–1917.
18 Hasegawa K, Kokudo N, Inamura H, Matsuyama Y, Aoki T, Minagawa M et al. Prognostic impact of anatomic resection for hepatocellular carcinoma. Ann Surg 2005; 242: 252–259.
19 Vauthey JN, Klimstra D, Franceschi D, Tao Y, Fortner J, Blumgart L et al. Factors affecting long-term outcome after hepatic resection for hepatocellular carcinoma. Ann J Surg 1995; 169: 28–34.
20 Waked T, Shirai Y, Sakata J, Kaneko K, Cruz PV, Akazawa K et al. Anatomic resection independently improves long-term survival in patients with T1–T2 hepatocellular carcinoma. Ann Surg Oncol 2007; 14: 1356–1365.
21. Kaibori M, Matsui Y, Hijikawa T, Uchida Y, Kwon AH, Kamiyama Y. Comparison of limited and anatomic hepatic resection for hepatocellular carcinoma with hepatitis C. *Surgery* 2006; **139**: 385–394.

22. Okamura Y, Ito T, Sugiura T, Mori K, Uesaka K. Anatomic versus nonanatomic hepatectomy for a solitary hepatocellular carcinoma: a case-controlled study with propensity score matching. *J Gastrointest Surg* 2014; **18**: 1994–2002.

23. Maruhashi S, Gotoh K, Akita H, Takahashi H, Ito Y, Yano M et al. Anatomical versus non-anatomical resection for hepatocellular carcinoma. *Br J Surg* 2015; **102**: 776–784.

24. Li SQ, Huang T, Shen SL, Hua YP, Hu WJ, Kuang M et al. Anatomical versus non-anatomical liver resection for hepatocellular carcinoma exceeding Milan criteria. *Br J Surg* 2017; **104**: 118–127.

25. Yune Y, Kim S, Song I, Chun K. Comparative analysis of intraoperative radiofrequency ablation versus non-anatomical hepatic resection for small hepatocellular carcinoma: short-term result. *Korean J Hepatobiliary Pancreat Surg* 2015; **19**: 173–180.

26. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. *Br J Surg* 1973; **60**: 646–649.

27. Makuuchi M, Kosuge T, Takayama T, Yamazaki S, Kakazu T, Miyagawa S et al. Surgery for small liver cancers. *Semin Surg Oncol* 1993; **9**: 298–304.

28. Wang Y, Luo Q, Li Y, Deng S, Wei S, Li X. Radiofrequency ablation versus hepatic resection for small hepatocellular carcinomas: a meta-analysis of randomized and nonrandomized controlled trials. *PLoS One* 2014; **9**: e84484.

29. Liu PH, Hsu CY, Hsia CY, Lee YH, Huang YH, Chiou YY et al. Surgical resection versus radiofrequency ablation for single hepatocellular carcinoma ≤ 2 cm in a propensity score model. *Ann Surg* 2016; **263**: 538–545.

30. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. *Lancet* 2012; **379**: 1245–1255.

31. Kokudo N, Hasegawa K, Akahane M, Igaki H, Izumi N, Ichida T et al. Evidence-based clinical practice guidelines for hepatocellular carcinoma: the Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines). *Hepatol Res* 2015; **45**.